Anti-NMDAR2A antibody [EPR2465(2)]
- 20ul selling size
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(58 Publications)
Rabbit Recombinant Monoclonal NMDAR2A antibody. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 58 publications.
View Alternative Names
NMDAR2A, GRIN2A, GluN2A, Glutamate [NMDA] receptor subunit epsilon-1, N-methyl D-aspartate receptor subtype 2A, NR2A, hNR2A
- WB
Lab
Western blot - Anti-NMDAR2A antibody [EPR2465(2)] (AB124913)
Exposure time
Lanes 1 to 2 : 40 seconds
Lanes 3 to 6 : 20 seconds
We recommend to use 1%SDS Hot lysis prepare method to get desired Western Blot results.
We are unsure how to define the extra bands.
All lanes:
Western blot - Anti-NMDAR2A antibody [EPR2465(2)] (ab124913) at 1/2000 dilution
Lane 1:
Human brain lysates prepared in RIPA lysis method at 20 µg
Lane 2:
Human brain lysates prepared in 1%SDS Hot lysis method at 20 µg
Lane 3:
Mouse brain lysates prepared in RIPA lysis method at 20 µg
Lane 4:
Mouse brain lysates prepared in 1%SDS Hot lysis method at 20 µg
Lane 5:
Rat brain lysates prepared in RIPA lysis method at 20 µg
Lane 6:
Rat brain lysates prepared in 1%SDS Hot lysis method at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 165 kDa
Observed band size: 165 kDa
false
- WB
Unknown
Western blot - Anti-NMDAR2A antibody [EPR2465(2)] (AB124913)
Blocking buffer : 5% NFDM/TBST
Dilution buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-NMDAR2A antibody [EPR2465(2)] (ab124913) at 1/20000 dilution
All lanes:
Human fetal brain tissue lysate at 10 µg
Secondary
All lanes:
HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 165 kDa
Observed band size: 165 kDa
false
- WB
Unknown
Western blot - Anti-NMDAR2A antibody [EPR2465(2)] (AB124913)
Blocking buffer : 5% NFDM/TBST
Dilution buffer : 5% NFDM/TBST
All lanes:
Western blot - Anti-NMDAR2A antibody [EPR2465(2)] (ab124913) at 1/1000 dilution
All lanes:
Human cerebellum tissue lysate at 10 µg
Secondary
All lanes:
HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 165 kDa
Observed band size: 165 kDa
false
- WB
Unknown
Western blot - Anti-NMDAR2A antibody [EPR2465(2)] (AB124913)
All lanes:
Western blot - Anti-NMDAR2A antibody [EPR2465(2)] (ab124913) at 1/1000 dilution
Lane 1:
Mouse brain lysate at 10 µg
Lane 2:
Rat brain lysate at 10 µg
Lane 3:
Human brain lysate at 10 µg
Secondary
All lanes:
HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 165 kDa
false
- OI-RD Scanning
Unknown
OI-RD Scanning - Anti-NMDAR2A antibody [EPR2465(2)] (AB124913)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
- WB
CiteAb
Western blot - Anti-NMDAR2A antibody [EPR2465(2)] (AB124913)
NMDAR2A western blot using anti-NMDAR2A antibody [EPR2465(2)] ab124913. Publication image and figure legend from Liang, L., Xie, R., et al., 2020, J Neurochem, PubMed 31705656.
ab124913 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab124913 please see the product overview.
Effects of antagonizing homodomain interacting protein kinase 2 on the synaptic toxicity of Sev. (a, b) Golgi staining and quantification of spines in control rats, Sev-treated, A64-treated, and Sev plus A64-treated rats. N = 6 rats per group. (c) Synaptic ultrastructure in hippocampus of control rats, A64-treated, Sev-treated, and Sev plus A64-treated rats. Notice that the decrease in spine number and PSD length were partially rescued by A64. N = 6 rats per group. (d, e) Western blot and quantification of Synaptophysin, post-synaptic density protein 95 (PSD95), calcium/calmodulin-dependent kinase II (CaMKII), phosphorylation of N-methyl-d-aspartate receptor subunit 2 A (pNR2A), NR2A and vesicular inhibitory amino acid transporter (vGAT). Notice that the decrease in Synaptophysin, PSD95, CaMKII, and pNR2A were partially rescued by A64. N = 6 rats per group. (f–h) Open field assay. N = 8 rats per group. (i–k) Elevated plus maze assay. Notice that A64 treatment alleviated the Sev-induced anxiety. N = 8 rats per group. (l–n) Morris water maze test. Notice that A64 treatment partially improved the spatial memory of Sev-treated rats. N = 8 rats per group. Con, control. Sev, Sevoflurane. *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001. #p < 0.05. One-way anova (a–n). Bar = 10 μm (a) and 200 nm (c).
false
Related conjugates and formulations (1)
-
Anti-NMDAR2A antibody [EPR2465(2)] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
NMDAR2A participates in synaptic signaling by forming part of the NMDA receptor complex. As part of this complex NMDAR2A interacts with other receptor subunits such as NR1 and NR2B which together modulate calcium influx into the neuron. This influx is essential for activating downstream signaling pathways that influence synaptic strength. The receptor's activation is tightly regulated which helps to maintain the balance between synaptic excitation and inhibition in the central nervous system.
Pathways
NMDAR2A serves essential roles in the long-term potentiation (LTP) and synaptic plasticity pathways. LTP is a process that strengthens synaptic connections and is important for memory formation. NMDAR2A interacts with proteins like postsynaptic density protein 95 (PSD-95) within these pathways to mediate downstream signaling events. It is also involved in the MAPK/ERK pathway affecting cellular processes such as gene expression differentiation and survival.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
- Download websiteProtocolBooklet|en
Target data
Publications (58)
Recent publications for all applications. Explore the full list and refine your search
Addiction neuroscience 15: PubMed40575352
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in pharmacology 16:1592187 PubMed40453656
2025
Applications
Unspecified application
Species
Unspecified reactive species
Autophagy 21:807-826 PubMed39635882
2024
Applications
Unspecified application
Species
Unspecified reactive species
Epigenetics 19:2417158 PubMed39460980
2024
Applications
Unspecified application
Species
Unspecified reactive species
Brain research 1845:149284 PubMed39423961
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of cellular biochemistry 126:e30664 PubMed39370692
2024
Applications
Unspecified application
Species
Unspecified reactive species
eLife 13: PubMed38963323
2024
Applications
Unspecified application
Species
Unspecified reactive species
ACS omega 9:21838-21850 PubMed38799363
2024
Applications
Unspecified application
Species
Unspecified reactive species
CNS neuroscience & therapeutics 30:e14611 PubMed38353051
2024
Applications
Unspecified application
Species
Unspecified reactive species
Annals of medicine and surgery (2012) 86:831-841 PubMed38333293
2024
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com